Background
==========

The immune system and the central nervous system (CNS) can affect one another both locally and systemically. For example, during a stroke, the immune response of the CNS induces activation of resident glia cells and macrophage \[[@B1]-[@B4]\], as well as the infiltration of circulating immune cells, respectively. A stroke is hypothesized to be a multiphasic process \[[@B5]\] and, in most cases, the cause of death results from inflammation without exogenous infection. Thus, a secondary component of ischemic brain injury may involve the effects of a significant inflammatory response.

In the first hours following stroke, rapid activation of resident microglia and production of pro-inflammatory cytokines occurs \[[@B6]\]. In addition, neutrophils and monocytes and/or macrophage infiltrate and accumulate in microvessels and in the ischemic cerebral parenchyma \[[@B7]\]. Accumulating evidence further suggests that the resulting inflammation response is responsible for inducing cerebral injury that is secondary to the hypoxia and ischemia that predominantly characterize a stroke event \[[@B8]\]. However, it is important to note that the action of the immune system is not uniform, and activation of immune cells may play different roles at different times.

Natural killer (NK) cells are a type of cytotoxic lymphocytes that play an important role in the innate immune system. For example, NK cells mediate a response to virally infected cells within three days of infection, and respond to tumor formation. The term 'natural killers', was coined based on the initial notion that these lymphocytes do not need to be activated to kill cells \[[@B9]\]. NK cells are key components of the innate immune system since they are able to rapidly produce an abundance of cytokines, mainly IFN-γ, and are able to lyse target cells without prior sensitization \[[@B10],[@B11]\]. The role of NK cells in the development of adaptive immune responses has also recently been shown \[[@B12]\].

Numerous observations have suggested that NK cells play a role in the adaptive immune response associated with autoimmune diseases. For example, the expansion of blood NK cells has been found to correlate with the suppression of disease activity, and NK cells isolated from patients during treatment were found to be highly activated \[[@B13]-[@B15]\].

While stroke is a disease that directly affects the neural system, it is also a type of autoimmune disease involving non-infection induced inflammation. Peterfalvi *et al.*\[[@B16]\] proved that NK cells and its fundamental cytokines decrease after stoke in human peripheral circulation. As cerebral ischemia is a kind of focal disease, focusing on changes in central system becomes necessary. Therefore, the objective of this study was to investigate the possible role of NK cells in stroke, including the timing of their infiltration into the brain, whether they mediate beneficial or harmful effects, what kind of role they may have in cerebral ischemia, and what kind of changes NK cells undergo during this process. Accordingly, functional alterations in cytokine and chemokine production by NK cells in both human and mouse models during the acute phase of ischemic stroke were examined.

Methods
=======

Animal experiments
------------------

Adult male C57/BL6 mice (weighing 20 to 25 g) were obtained from Peking Vital River Laboratory Animal Ltd (Beijing, People's Republic of China). All mice were bred and maintained in accordance with the guidelines of the Care and Use of Laboratory Animals published by the China National Institute of Health. Furthermore, all experiments were conducted in accordance with institutional guidelines and were approved by Harbin Medical University ethics committee. A permanent middle cerebral artery occlusion (pMCAO) mouse model was established using the intraluminal filament method (6--0 nylon) as previously described \[[@B17]\]. In the sham group arteries were blunt dissected, yet not ligated. Following surgery, each mouse was assessed on a scale from 0 to 5 upon awakening, and only mice receiving a score of \> 1 were included in this study \[[@B18]\].

Immunohistochemistry and immunofluorescence staining for NKp46, IP-10, CXCR3 and IFN-γ
--------------------------------------------------------------------------------------

Human samples were provided by the Department of Neurosurgery, The First Clinical College of Harbin Medical University and were used for our research which was approved by the Harbin Medical University ethics committee. Patient deaths were identified as due to cerebral ischemic infarction and were diagnosed using computerized tomography. Tissue samples were taken from an area adjacent to the infarct site, and also from a similar area on the normal contralateral hemisphere, from each human brain sample. Tissues were embedded in paraffin and sectioned (10 μm). Frozen CNS material from mouse models were obtained after autopsy. Briefly, after being fixed in cold acetone for 20 minutes, tissues were blocked in 5% horse serum for 1 hour at room temprature, and were then permeabilized with 0.1% Triton X-100 (Sigma, St. Louis, USA) for 30 minutes. Primary antibodies used included: goat anti-mouse/human NKp46 (1/150, Santa Cruz, Dallas, USA), goat anti-mouse/human IP-10 (1/150, Santa Cruz, Dallas, USA), rabbit anti-mouse CXCR3 (1/150, Santa Cruz, Dallas, USA), and rat anti-mouse IFN-γ (1/150, Biolegend, San Diego, USA). Tissues were incubated with antibodies overnight at 4°C. After several washes with phosphate buffing saline (PBS), the appropriate secondary antibodies were applied (1:200, Zhongshan Goldenbridge Biotechnology Co. Ltd., Beijing, People's Republic of China). Nuclei were co-stained with 4,6-diamidino-2-phenylindole (DAPI). Control stainings included the omission of primary antibody. The human tissue section areas were measured by image analysis software (Image Pro Plus 5.0, Media Cybernetics, Warrendale, USA). The numbers of stained cells per mm^2^ of tissue area were calculated.

2,3,5-triphenyltetrazolium chloride staining
--------------------------------------------

Mice were euthanized 12 hours after pMCAO under deep anesthesia with sodium pentobarbital (60 mg/kg body weight). Brains were rapidly removed after intracardial infusion of PBS. The brains were then cut on the coronal suture into five slices, using a brain slicer. Brain slices were immediately incubated in 2,3,5-triphenyltetrazolium chloride (TTC) solution (2% solution in PBS) for 30 minutes at 37°C. Areas not stained red with TTC were considered to be damaged.

Primary cultures of neural cells
--------------------------------

Neural cell cultures were prepared from newborn C57/BL6 mice. Soon after discarding the meninges, the mesencephalon, cerebellum, and brain stem, cortexes were blunt isolated from the cerebrum and then gently pipetted to achieve a single cell suspension in 10% DMEM (supplemented with 10% FCS, 100 U/ml penicillin, 0.1 mg/ml streptomycin). Cell suspensions were passed through a 150 μm nylon filter, then were seeded in 24-well plates (5 × 10^4^ cells/well) or 25 mm^2^ flasks (10^5^/ml) coated with D-polylysine (PDL), and were cultured for at least 7 days.

Flow cytometry
--------------

Mice were euthanized and perfused with PBS. Hemispheres were divided to isolate non-ischemic (ipsilesional) and ischemic (contralesional) tissue samples. Three to four hemispheres were pooled for each treatment group, and the resulting homogenates were pressed through 150 μm and 75 μm filters. Next, cells were separated from myelin and debris using 70% and 30% Percoll (GE Healthcare, Pittsburgh, USA) gradients, respectively, followed by centrifugation. Samples were then incubated with anti-mouse NKp46 antibody (Santa Cruz, Dallas, USA) for 30 minutes at RT in a fluorescence-activated cell sorter (FACS) buffer (0.1% bovine serum albumin (BSA), 0.01% sodium azide in PBS). After the cells were washed twice with wash buffer (0.1% BSA/PBS), FITC-conjugated anti-goat secondary antibodies (Biolegend, San Diego, USA) were applied for 30 minutes at RT. Finally, the cells were fixed with 2% paraformaldehyde at 4°C, and were then analyzed by blinded evaluators using a FacsCalibur (BD Biosciences, Franklin Lakes, USA) and FlowJo software (ThreeStar Inc., Ashland, USA) Three independent experiments were performed for all time points, and 3 to 4 mice were used per experiment.

Neural cells for apoptosis detection were prepared from newborn C57/BL6 mice as previously described, and were cultured in 10% DMEM until they covered the bottom of a 25 mm^2^ flask. Cells were then treated with NK cells (10^5^) harvested from C57/BL6 12 weeks mice' spleens with a MagCellect Mouse NK Cell Isolation Kit (R&D, Minneapolis, USA) and murine IFN-γ neutralizing antibody (10 ng/ml, R&D, Minneapolis, USA) in 10% DMEM, then stained with a PI/Annexin kit (BD Biosciences, Franklin Lakes, USA). Stained cells were detected by evaluators who have no relationship with this experiment using a FacsCalibur (BD Biosciences, Franklin Lakes, USA) and FlowJo software. Three independent experiments were performed.

NK cells harvested from 12-week old C57/BL6 mice spleens with a MagCellect Mouse NK Cell Isolation Kit (R&D, Minneapolis, USA) were treated with murine IP-10 (10 ng/ml, 50 ng/ml, 100 ng/ml) accompanied by 6 hour oxygen glucose deprivation (OGD) in Hank's Balanced Salt Solution (HBSS) (Ca-Mg-free, glucose 1 g/L). Mean fluorescence of CXCR3 (PE) which NK cells presented were blinded evaluators using a FacsCalibur (BD Biosciences, Franklin Lakes, USA) and FlowJo software. Three independent experiments were performed. Non-OGD groups were cultured in a cell incubator (5%CO~2~) in HBSS (Ca-Mg-free, 1 g/L glucose). Three independent experiments were performed.

Reverse transcription PCR
-------------------------

Total RNA from the whole cortex, which had been sorted in pMCAO mice, was obtained at different time points using a Trizol extraction method recommended by Invitrogen. Reverse transcription was performed using an RT-PCR kit from TaKaRa (Kusatsu, Japan). PCR amplification of IP-10,IFN-γ, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (endogenous control) were achieved using Taq polymerase and the following primers: IP-10 sense 5′-GCC GTC ATT TTC TGC CTC AT-3′ and anti-sense 5′-GCT TCC CTA TGG CCC TCA TT-3′, IFN-γ sense 5′-AGC GGC TGA CTG AAC TCA GAT TGT-3′ and anti-sense 5′-GTC ACA GTT TTC AGC TGT ATA GGG-3′, and GAPDH sense 5′-AAT GCA TCC TGC ACC AA-3′ and anti-sense 5′-TCC ACC ACC CTG TTG CTG TA-3′. A total of 40, 40 and 32 cycles were performed for IP-10, IFN-γ and GAPDH, respectively. Three independent experiments were performed.

Migration assays
----------------

Neural cells (5 × 10^4^ cells) prepared from newborn C57/BL6 mice as previously described were seeded in the bottom of 24-well transwell plates. After culturing the cells for at least 7 days, mouse brain endothelial cells (bEnd3, ADCC) (1 × 10^4^) were plated on top of 2% gelatin-coated 3 μm pore size upper transwell chambers with 10% DMEM media. After the ECs formed a confluent monolayer, 20 ng/ml murine IP-10 neutralization antibody (R&D, Minneapolis, USA) was added to the lower chambers when appropriate. Simultaneously, a suspension of NK cells (1 × 10^6^/ml; 100 μl) prepared from 12-week old C57/BL6 mice spleens with a MagCellect Mouse NK Cell Isolation Kit (R&D, Minneapolis, USA) were added to the upper chamber. The ability of NK cells to cross the monolayer was evaluated by counting the absolute number of cells that migrated to the lower chamber after OGD conditions were applied for 6 hours in HBSS (Ca-Mg-free, 1 g/L glucose). Furthermore, the cells in the upper chamber were indirectly labeled with NKp46-FITC, cell counts were performed using FACS, and three independent experiments were performed. Non-OGD groups were cultured in a cell incubator (5%CO~2~) in HBSS (Ca-Mg-free, 1 g/L glucose).

Permeability assays
-------------------

Permeability assays were conducted as previously described \[[@B19]\]. Soon after 6 hours OGD in HBSS (Ca-Mg-free, 1 g/L glucose), 50 μg/ml fluorescein isothiocyanate-labeled BSA (FITC-BSA, Sigma, St. Louis, USA) was added to the upper chamber of transwells. Samples (both 50 μl) were then obtained from the upper and lower chambers of each well and the fluorescence intensity of these samples was measured using a FL600 microplate fluorescent reader (Biotek, Vermont, USA). The diffusion rate, representing the permeability of blood brain barrier (BBB) endothelial cells (ECs), was expressed as a percentage and was calculated as follows: (BSA lower chamber) × 100 / (BSA upper chamber). Non-OGD groups were cultured in a cell incubator (5%CO~2~) in HBSS (Ca-Mg-free, 1 g/L glucose).Three independent experiments were performed.

*In vivo* NK depletion assay
----------------------------

Depletion of NK cells *in vivo* in mice was induced by intraperitoneal injection (i.p.) of a depleting anti-NK1.1 mAb (clone PK136, Biolegend, San Diego, USA). The depleting antibody was given at 0.5 mg i.p. 1 day before the pMCAO mouse model (12 hours) was established as previously described. The lymphocytes infiltration assay was then performed via FACS, and IFN-γ expression level was detected by RT-PCR as previously described.

*In vivo* IP-10 depletion assay
-------------------------------

To block IP-10 *in vivo*, mice were injected intravenously with 3 mg/100 g body weight anti-mouse IP-10 (R&D Systems) for two days to neutralize the IP-10 secretion before the pMCAO mouse model was established as previously described, and the lymphocytes infiltration assay was then performed via FACS.

Statistical analysis
--------------------

Results are expressed as the mean ± standard deviation (SD). An analysis of variance (ANOVA) test was used to compare multiple quantitative variables. Statistical analysis was performed using one-way ANOVA analysis of variance followed by Student's t-test. Statistical significance was considered to be *P* \< 0.05.

Results
=======

NK cells participate in cerebral ischemia
-----------------------------------------

Paraffin-embedded human brain tissues affected by cerebral ischemic infarction, as well as contralateral tissues, were divided into three groups according to the period of time that elapsed between the onset of stroke and death. These groups included: \<2 days, 2 to 5 days, and \>5 days, with 5, 11, and 4 sets of patient tissues included in each group, respectively (Table  [1](#T1){ref-type="table"}, 1--20). Immunohistochemistry staining of NK cells was performed for each tissue set (Figure  [1](#F1){ref-type="fig"}A,B), and the number of NK cells in the ischemic hemispheres was found to be significantly greater than those in the non-ischemic hemispheres (*P*~\<\ 2\ days~ \< 0.05, *P*~2\ to\ 5\ days~ \< 0.01, *P*~*\>*5\ days~ \< 0.05). Furthermore, the highest numbers of NK cells were observed in the 2 to 5 days tissues (Figure  [1](#F1){ref-type="fig"}C).

###### 

Clinical data from stroke patients

   **Number**   **Serial number**   **Gender**   **Age**     **Diagnosis**      **First or recurrent cerebrovascular accident**                                                                                           **Medications**
  ------------ ------------------- ------------ --------- -------------------- ------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
       1              A223             Male        60       Ischemic stroke                          First                                                               Mannitol, Lasix, buffered glycerol saline, Coraminum, lobeline, glucose, insulin, mefoxinvial, albumin, urokinase
       2              A593            Female       65       Ischemic stroke                        Recurrent                                                                   Mannitol, Xuesaitong injection, CDPC, urokinase, Dextran, insulin, cephalosporin, Coraminum, lobeline
       3              A437            Female       48       Ischemic stroke                          First                                                                        Mannitol, Lasix, buffered glycerol saline, Coraminum, lobeline, glucose, insulin, mefoxin vial
       4              A225            Female       63       Ischemic stroke                        Recurrent                                                                                         mannitol, Lasix, Dexamethasone, Saline, Sodium Valproate
       5              A351            Female       44       Ischemic stroke                          First                                                                                                          Saline, ahylysantinfarctase
       6              A368             Male        65       Ischemic stroke                          First                                                                                                     mannitol, Lasix, Coraminum, lobeline
       7              A375             Male        60      Hemorrhagic stroke                        First                                                                                                      mannitol , PAMBA, Lasix, cedilanid
       8              A388            Female       56       Ischemic stroke                          First                                               Mannitol, Lasix, buffered glycerol saline, urokinase, glucose, cephalosporin, Dextran, CompoundDanshen, Nao Mai Tong recipe, Coraminum, lobeline
       9              A389            Female       68       Ischemic stroke                          First                                                                                        Mannitol, Lasix, buffered glycerol saline, Coraminum, lobeline
       10             A405            Female       56       Ischemic stroke                          First                                                     Mannitol, Lasix, buffered glycerol saline, Sodiumcytidine diphosphate choline injection, cephalosporin, Coraminum, lobeline, insulin
       11             A422             Male        43       Ischemic stroke                          First                                              cidilaniol, glucose, injcinetodini, coramini, lobeline, Saline, dopamim, aramim, ritalim, atropiai, epinephrine, sodium bicarbonate, noradrenaline
       12             A432             Male        64       Ischemic stroke                        Recurrent                      Saline, ahylysantinfarctase, mannitol, Lasix, Coraminum, glucose, injcinetodini, coramini, lobeline, Saline, dopamim, aramim, ritalim, atropiai, epinephrine, sodium bicarbonate, noradrenaline
       13             A597             Male        64       Ischemic stroke                        Recurrent                                                                  Mannitol , Xuesaitong injection, CDPC, urokinase, Dextran, insulin, cephalosporin, Coraminum, lobeline
       14             A598             Male        48       Ischemic stroke                          First                                                                        Mannitol, Lasix, buffered glycerol saline, Coraminum, lobeline, glucose, insulin, mefoxin vial
       15             A599             Male        67       Ischemic stroke                        Recurrent                                                                       Mannitol, Lasix, buffered glycerol saline, Coraminum, lobeline, glucose, mefoxinvial, albumin
       16             A600            Female       61       Ischemic stroke                          First                                                               Mannitol, Lasix, buffered glycerol saline, Coraminum, lobeline, glucose, insulin, mefoxinvial, albumin, urokinase
       17             A601             Male        67       Ischemic stroke                          First                                                              Mannitol, Lasix, buffered glycerol saline, Coraminum, lobeline, glucose, mefoxinvial, urokinase, Losec, Cimetidine
       18             A602             Male        67       Ischemic stroke                          First                                                                                                      Mannitol, Lasix, Nimotop, Aspirin,
       19             A610             Male        63       Ischemic stroke                        Recurrent                                                                                                             Insulin, glucose,
       20             A625            Female       63       Ischemic stroke                          First                                                               Mannitol, Lasix, buffered glycerol saline, Coraminum, lobeline, glucose, insulin, mefoxinvial, albumin, urokinase
       21             A634            Female       70       Ischemic stroke                          First                                                                                     Mannitol, Lasix, urokinase, Nitroprusside, insulin, insulin, dopamim
       22             A647             Male        60       Ischemic stroke                          First                                                                                           Nimotop, Losec, Coraminum, lobeline, Citicoline, mannitol
       23             A648            Female       47       Ischemic stroke                          First                                                                                            Lasix, Luminal, urokinase, insulin, glucose, KCl, NaCl
       24             A655             Male        66       Ischemic stroke                        Recurrent                                Saline, ahylysantinfarctase, mannitol, Lasix, Coraminum, glucose, injcinetodini, coramini, lobeline, Saline, dopamim, ritalim, atropiai, sodium bicarbonate, noradrenaline
       25             6571            Female       53       Ischemic stroke                          First                                                                  Mannitol, Lasix, buffered glycerol saline, urokinase, glucose, cephalosporin, Dextran, Coraminum, lobeline
       26             6572            Female       56       Ischemic stroke                          First                                                          Mannitol, Lasix, buffered glycerol saline, urokinase, glucose, cephalosporin, Dextran, CompoundDanshen, Coraminum, lobeline
       27             6573            Female       73       Ischemic stroke                          First                                                                                              Mannitol, Lasix, urokinase, Nitroprusside, dopamim
       28             6574             Male        62       Ischemic stroke                        Recurrent                                                                                               Mannitol, Lasix, urokinase, insulin, glucose,
       29             6575             Male        59      Hemorrhagic stroke                        First                                                                                                       Mannitol, PAMBA, Lasix, cedilanid
       30             6576             Male        66       Ischemic stroke                        Recurrent                                                                      Mannitol, Xuesaitong injection, urokinase, Dextran, insulin, cephalosporin, Coraminum, lobeline
       31             6577            Female       49       Ischemic stroke                          First                                                                               Mannitol, Lasix, buffered glycerol saline, Coraminum, lobeline, glucose, insulin
       32             6578             Male        64       Ischemic stroke                        Recurrent                                                                                        Mannitol, Lasix, buffered glycerol saline, insulin, glucose
       33             6579            Female       45       Ischemic stroke                          First                                                                        Mannitol, Lasix, buffered glycerol saline, Coraminum, lobeline, glucose, insulin, mefoxin vial

![**NK cells participate in cerebral ischemia. (A,B)**: NK cells stained brown in ischemic tissues (magnification, 400×). Differences between the ischemic **(A)** and non-ischemic **(B)** hemispheres were significant for the 2 to 5 day group, and were fewer in the non-ischemic hemispheres; **(C)**: Infiltration of NK cells into human ischemic tissue. The highest number of NK cells were detected in the 2 to 5 day group; **(D,E)**: NK cells in mouse ischemic tissue penumbra. NK positive cells (FITC) were found in ischemic tissues **(D)** (bar = 30 μm); **(F)**: Infiltration of NK cells detected in mouse ischemic tissue by FACS; **(G)**: Of the infiltrating lymphocytes detected, the percentage of NK cells is reported; **(H)**: After NK cells depletion *in vivo*, infiltration of NK cells detected in mouse ischemic tissue by FACS; **(I)**: Representative TTC-stained sections of NK cells depletion mouse at 12 hours following pMCAO. (\**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001, compared with the corresponding values for the contralateral hemispheres). pMCAO, permanent middle cerebral artery occlusion.](1742-2094-11-79-1){#F1}

Next, the infiltration of NK cells was examined in a C57/BL6 pMCAO model. NK cells were detected in ischemic brain tissues, and these cells were consistently observed in proximity of the ischemic penumbra (Figure  [1](#F1){ref-type="fig"}D,E). To monitor NK cells during ischemia, infiltrating cells were isolated from the cerebrum at various timepoints and were analyzed by flow cytometry. Based on the FACS data obtained, the infiltration of NK cells peaked 12 hours after ischemia, and the number of NK cells in the ischemic hemisphere was significantly greater than that of the non-ischemic hemisphere 12, 24, 48, and 96 hours after ischemia (*P*~12\ hours~ \< 0.01, *P*~24\ hours~ \< 0.001, *P*~48\ hours~ \< 0.05, *P*~96\ hours~ \< 0.05) (Figure  [1](#F1){ref-type="fig"}F). Moreover, the percentage of NK cells among the infiltrating cells recovered was highest 12 hours after ischemia, and decreased at the subsequent timepoints (Figure  [1](#F1){ref-type="fig"}G). After NK cells depletion, NK cells infiltration notably decrease in ischemic mouse brain at 12 hours (Figure  [1](#F1){ref-type="fig"}H, *P* \< 0.001), and the ischemia area diminished with TTC staining (Figure  [1](#F1){ref-type="fig"}I).

NK cells negatively affect neural cells via IFN**-γ**
-----------------------------------------------------

IFN-γ is one of the main cytokines secreted by NK cells. Using immunofluorescence assays and FACS, IFN-γ-positive NK cells present in ischemic tissues were analyzed 12, 24, 48, and 96 hours after ischemia (Figure  [2](#F2){ref-type="fig"}A,B). The highest levels of IFN-γ-positive NK cells were detected 12 and 72 hours after ischemia (*P*~12\ hours~ \< 0.01, *P*~72\ hours~ \< 0.01) (Figure  [2](#F2){ref-type="fig"}C).

![**NK cells promote neural necrosis via IFN-γ. (A)**: NK cells express IFN-γ in mouse ischemic cerebral tissue (bar = 20 μm); **(B,C)**: Infiltration of IFN-γ/NK positive cells in mouse ischemic brain detected by FACS at different time points; **(D,E)**: Percentage of neuronal cells undergoing apoptosis (A) and necrosis (N) after NK cells were co-cultured with or without IFN-γ; **(F)**: Levels of IFN-γ mRNA detected in mouse ischemic hemispheres by PCR after NK cells depletion *in vivo*; (\*\**P* \< 0.01, \*\*\**P* \< 0.001, compared with the corresponding values of the contralateral hemispheres).](1742-2094-11-79-2){#F2}

Staining for apoptosis and necrosis, we found levels of necrosis of neural cells significantly increased after adding NK cells, compared with the control group (only neural cells), meanwhile levels of apoptosis were quite low(*P* \< 0.001). However, after treatment with IFN-γ blockade, levels of apoptosis significantly increased and levels of necrosis became lower in the NK + IFN-γ blockade group, compared to the NK co-culture group (*P*~*N*~ \< 0.01, *P*~*A*~ \< 0.001), while levels of necrosis and apoptosis did not differ from the control group (Figure  [2](#F2){ref-type="fig"}D,E). After NK cells depletion, the level of IFN-γ mRNA expression decreased at 12 hours (Figure  [2](#F2){ref-type="fig"}F).

Chemotactic effect of IP-10 on NK cells via CXCR3 during cerebral ischemia
--------------------------------------------------------------------------

A second set of human brain tissue samples were obtained, and these derived from patients that died \<7 days, between 7 and 14 days, or \>14 days after experiencing an ischemic event. There were four, five, and four tissue sets for each group, respectively (Table  [1](#T1){ref-type="table"}, 21--33). Immunohistochemistry assays were performed, including the staining of IP-10 (Figure  [3](#F3){ref-type="fig"}A,B). A significantly higher number of IP-10-positive cells were detected in the ischemic hemispheres compared to the contralateral hemispheres among these three groups. In addition, IP-10-positive cells in the ischemic hemisphere tissues of the \<7 day group were very high, and the IP-10-positive cells in the ischemic hemisphere tissues of the 7 to 14 days group were present at lower levels compared to the \>14 day group (Figure  [3](#F3){ref-type="fig"}C, *P*~\<7day~ \< 0.01, *P*~7\ to\ 14\ day~ \< 0.05, *P*~15\ to\ 21\ day~ \< 0.01).

![**Chemotactic effect of IP-10 on infiltrating NK cells during cerebral ischemia. (A,B)**: Expression of IP-10 in ipsilesional **(A)** and contralesional **(B)** hemispheres after stroke (magnification, 400×). **(C)**: Significant differences between ipsilesional and contralesional hemispheres were observed. **(D-G)**: Immunofluorescence detection of IP-10-positive cells (FITC) in mouse ischemic penumbra collected at different time points (bar = 20 μm). **(H)**: Levels of IP-10 mRNA detected in mouse ischemic hemispheres by PCR; **(I)**: Interaction between IP-10 and infiltrating NK cells; **(J)**: Infiltration of NK cells detected in mouse ischemic tissue by FACS after IP-10 depletion *in vivo*. (\*\**P* \< 0.01, \*\*\**P* \< 0.001, compared with the corresponding values of the contralateral hemispheres).](1742-2094-11-79-3){#F3}

Immunofluorescence assays were also performed for ischemic brain sections of pMCAO C57/BL6 mice. In these studies, IP-10 expressing cells were observed to localize to the ischemic penumbra, as well as to the sagittal suture, at different time points (Figure  [3](#F3){ref-type="fig"}D,G). PCR assays demonstrated that levels of IP-10 mRNA were highest 12 hours after ischemia, especially in the ischemic hemisphere tissues (Figure  [3](#F3){ref-type="fig"}H). Furthermore, the number of NK cells present in the ischemic and contralateral hemispheres of pMCAO mouse tissues was also detected by FACS, and a similar observation was made, with a greater number of NK cells detected in ischemic tissues than contralateral tissues. Taken together, the relationship between IP-10 levels and NK levels was found to be significant (Figure  [3](#F3){ref-type="fig"}I, *P* \< 0.001). Then we blocked IP-10 *in vivo* at the 12 hour time point, the number of NK cells present in the ischemic hemispheres of pMCAO mouse tissues were significantly low (*P* \< 0.001) which were detected by FACS(Figure  [3](#F3){ref-type="fig"}J, *P* \< 0.001).

In our laboratory, IP-10 has been found to be produced by local cells (glial cells and endothelial cells) in an inflammatory lesion and cells culture supernatants (data not shown). Therefore, expression of the receptor for IP-10, CXCR3, was assayed using immunohistochemistry. In mouse pMCAO brain tissue, CXCR3-positive infiltrating NK cells were detected (Figure  [4](#F4){ref-type="fig"}A). NK cells were then treated with various concentrations of murine IP-10 (such as 10 ng/ml, 50 ng/ml, 100 ng/ml, Peprotech, USA) and subjected to 6 hour OGD conditions. Detection of the mean fluorescence value for CXCR3 indicated that CXCR3 expression in 100 ng/ml group significantly increased when compared with 50 ng/ml group (*P* \< 0.001), and as the concentration of IP-10 increased, the mean fluorescence value of CXCR3 got higher. Furthermore, this number was enhanced when NK cells were deprived of oxygen (Figure  [4](#F4){ref-type="fig"}B).

![**NK cells were absorbed by IP-10 via the linkage of CXCR3. (A)** Immunofluorescence assays of NKp46 and CXCR3 in mouse ischemic cerebral tissue (bar = 20 μm); **(B)** The dose-dependent effect of IP-10 on NK cells. (\**P* \< 0.05, \*\*\**P* \< 0.001).](1742-2094-11-79-4){#F4}

NK cells accelerate BBB injury via IP-10 chemotaxis
---------------------------------------------------

An *in vitro* model of the BBB was established with brain microvascular endothelial cells plated in the upper chambers of transwells, and neural cells plated in the lower chambers. Upon reaching confluence, the medium was changed to Ca-Mg-free HBSS (1 g/L glucose), and NK cells were added to the upper chamber. Cells were then subjected to OGD conditions. Using permeability assays, brain microvascular endothelial cells were found to be affected by the presence of NK cells after OGD (Figure  [5](#F5){ref-type="fig"}A, *P* \< 0.01), suggesting that NK cells not only negatively affect neural cells, but may also affect the BBB during ischemia.

![**IP-10 promotes NK cell-induced BBB injury. (A)**: IP-10 blockade attenuated a BBB permeability injury induced by NK cells under OGD treatment. **(B)**: Migration of NK cells with or without IP-10 blockade with OGD treatment. (\**P* \< 0.05, \*\**P* \< 0.01). BBB, blood brain barrier; OGD, oxygen glucose deprivation.](1742-2094-11-79-5){#F5}

To investigate the effect of IP-10 on NK cells, IP-10 antibody was added to the lower chamber of the BBB model to neutralize the IP-10 secreted by neural cells (results not shown). The permeability rate of this model subsequently decreased according to the BSA diffusion assay performed (Figure  [5](#F5){ref-type="fig"}A, *P* \< 0.05). FACS of neural cells in the lower chamber also detected a lower percentage of NK cells, thereby suggesting that the IP-10 blockade can inhibit the migration of NK cells through the BBB (Figure  [5](#F5){ref-type="fig"}B, *P* \< 0.05).

Discussion
==========

Peterfalvi *et al.*\[[@B16]\] previously demonstrated that NK cells are active during the acute phase of stroke. In addition, when NK cells were isolated from the peripheral circulation during the early phases of stroke, deficient IFN-γ production and cytotoxicity were observed, similar to that observed in animal models \[[@B20]\]. Additional reports have shown that while numbers of NK cells remain unchanged following stroke, numbers of adaptive T lymphocyte subsets decrease \[[@B21]-[@B23]\]. The objective of this study was to examine the role of NK cells in brain tissue affected by ischemia. During the early phases of stroke, a peak in the infiltration of NK cells was observed, concomitant with increased expression of IFN-γ (Figure  [1](#F1){ref-type="fig"}A-C; Figure  [2](#F2){ref-type="fig"}A-C). Based on these results, we hypothesized that NK cells play an important role during the onset of cerebral ischemia. In studies by Gelderblom *et al.*\[[@B24]\], NK cells were not found to significantly affect ischemia in a mouse brain 1 hour after the ischemic event and reperfusion. In the present study, numbers of infiltrating NK cells reached their highest levels in the ischemic hemisphere 12 hours after the ischemic event (*P \<* 0.01) (Figure  [1](#F1){ref-type="fig"}F) according to FACS analysis. Furthermore, IFN-γ-positive NK cells exhibited a similar profile (Figure  [2](#F2){ref-type="fig"}C). The analysis of NK cells as a percentage of infiltrating lymphocytes further confirmed that NK cells have a predominant role during the onset of stroke (Figure  [1](#F1){ref-type="fig"}G). After we depleted NK cells *in vivo*, NK infiltration in ischemic brain got notably lower (Figure  [1](#F1){ref-type="fig"}H) as did the level of IFN-γ mRNA (Figure  [2](#F2){ref-type="fig"}F), and the ischemia area diminished, which strengthens the importance of NK cells participation in the onset of cerebral ischemia.

Interestingly, when neural cells were exposed to activated NK cells, an increase in the number of dead cells and very low levels of apoptosis were observed. In contrast, a significant increase in the levels of apoptosis was detected following neutralization of IFN-γ secreted by NK cells (Figure  [2](#F2){ref-type="fig"}D,E). Apoptosis is currently recognized as a necessary process during the development of the nervous system \[[@B25]\]. Moreover, the apoptosis of neural cells is anticipated to stabilize a microenvironment more so than the presence of dead neural cells. Therefore, we hypothesize that NK cells promote the necrosis of neural cells via IFN-γ during the early stages of stroke, and the fragments of these dead cells negatively affect the ischemic region. Accordingly, neutralization of IFN-γ in the brain should be further investigated in clinical trials.

The detection of NK cells in ischemic brain tissue illustrates that NK cells have a role in cerebral ischemia, and the section of IFN-γ by NK cells has the potential to affect neural cells. However, previous studies have not demonstrated how NK cells are able to access ischemic tissues. Since blood flow is blocked following an ischemic event, access via circulation is not a possibility. IP-10 is a chemoattractant secreted by several cell types in response to IFN-γ, and these cell types include monocytes, endothelial cells, and fibroblasts \[[@B26]\]. Furthermore, IP-10 has been identified as a chemoattractant for monocytes and macrophages, T cells, NK cells, and dendritic cells \[[@B27]\]. IP-10 has been proven to increase in focal stroke \[[@B28]-[@B30]\]. In our study, we focused on probing the relationship between IP-10 and NK cells accumulation after stroke. IP-10 was detected in human ischemic brain tissue (Figure  [3](#F3){ref-type="fig"}A,B), and was present at high levels during the early stages of stroke (Figure  [3](#F3){ref-type="fig"}C). Similarly, IP-10 was detected in ischemic cerebral tissue of the mouse model examined (Figure  [3](#F3){ref-type="fig"}D,G), with the highest levels detected 12 hours after ischemia using RT-PCR. These results are consistent with the rat model of ischemia characterized by Wang *et al.*\[[@B31]\] (Figure  [3](#F3){ref-type="fig"}H), and the decrease of NK cells infiltration in ischemic brain after IP-10 depletion *in vivo* prompt us to compare relationship between IP-10 and NK cells when stroke occurs, suggesting that IP-10 expression induces NK cell infiltration following cerebral ischemia (Figure  [3](#F3){ref-type="fig"}I,J).

CXCR3 regulates leukocyte trafficking, and binding of chemokines such as IP-10 can induce various cellular responses \[[@B32]\]. Most notably, these changes can include integrin activation, cytoskeletal changes, and chemotactic migration. However, these responses are restored following the dephosphorylation of intracellular receptors and their subsequent recycling to the cell surface. In the present study, detection of mean fluorescence intensity was used to evaluate the action of IP-10 on NK cells. As a result, IP-10 was found to activate CXCR3 expression by NK cells (Figure  [4](#F4){ref-type="fig"}A), and this effect was dose-dependent (Figure  [4](#F4){ref-type="fig"}B). However, IFN-γ-mediated cytoxicity associated with IP-10-induced activation of NK cells was not observed (data not shown). Therefore, it appears that IP-10 is only a chemotactic cytokine for NK cells following cerebral ischemia.

NK cells respond to several chemotactic factors, including MIP-1 and Mig \[[@B33]\]. However, IP-10 is the primary chemotactic factor for NK cells in the brain. In the present study, IP-10 was found to be primarily secreted by neural cells rather than brain microvascular endothelial cells under OGD conditions (data not shown). In the brain, the stability of the microenvironment is maintained by BBB permeability \[[@B34]\]. Correspondingly, damage to the BBB can promote secondary inflammation injury following stroke \[[@B35]\]. By co-culturing neural cells and cerebral microvascular endothelial cells under OGD conditions as an analogue of ischemia and the BBB, an increase in permeability was observed following the addition of NK cells (Figure  [5](#F5){ref-type="fig"}A). Furthermore, this increase in permeability, as well as the migration of NK cells, was reduced following neutralization of IP-10 (Figure  [5](#F5){ref-type="fig"}B). These results strongly suggest that NK cells negatively affect the BBB during stroke, and IP-10 enhances the infiltration of NK cells through the BBB following cerebral ischemia.

Conclusions
===========

In summary, NK cells were found to participate in the early stages of stroke and to induce the necrosis of neural cells via IFN-γ. Based on these results, the capacity to neutralize IFN-γ represents an opportunity to stabilize the microenvironment associated with cerebral ischemia. In addition, NK cells were found to damage the BBB in response to IP-10 as a chemoattractant. These results suggest that the damage mediated by NK cells following stroke may be attenuated by neutralizing IP-10 and other factors that are attractive to NK cells, thereby preventing the release of cytotoxic cytokines. It is anticipated that further studies of these mechanisms may improve the indications of clinical therapy for brain ischemia. Furthermore, future studies will need to focus on NK cells present in ischemic tissue and their interactions with other immune cells during different phases of stroke, particularly interactions that lead to damage of the BBB.
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